butyl N-isopropyl carbamate | 18312-36-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: butyl N-isopropyl carbamate
• 英文别名: Butyl propan-2-ylcarbamate；butyl N-propan-2-ylcarbamate
• CAS: 18312-36-2
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: JMEJUPWADBAAIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  丁基二氯甲基碳酸酯 、 异丙胺 以 甲苯 为溶剂， 反应 8.0h， 以68.5%的产率得到butyl N-isopropyl carbamate
  参考文献：
  名称：

  α-卤代烷基卤甲酸酯和相关化合物。二、二氯甲基碳酸酯的合成及其向氨基甲酸酯的转化

  摘要：

  摘要 用氯甲酸二氯甲酯处理醇后很容易得到碳酸二氯甲酯，在温和条件下与各种胺反应生成氨基甲酸酯，收率高。还演示了从 2-氨基醇合成恶唑酮的反应的扩展。

  DOI：

  10.1080/00397919408010561

文献信息

• HIV REPLICATION INHIBITOR
  申请人：Shionogi & Co., Ltd.

  公开号：US20140249306A1

  公开（公告）日：2014-09-04

  The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein, a broken line means the presence or absence of a bond; R 1 is substituted or unsubstituted alkyl etc., R 2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R 3 is a substituted or unsubstituted aromatic carbocyclic group; R 4 is a hydrogen atom etc.; R 5 is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R 6 is substituted or unsubstituted alkyl; R 7 is —Z—R 71 etc.; Z is —NR 72 —CO— etc.; R 71 is substituted or unsubstituted alkyl etc.; R 72 is a hydrogen atom etc.

  本发明提供了一种具有抗病毒作用的新化合物，特别是具有抑制HIV复制作用的化合物，以及一种药物组合物，特别是一种抗HIV药物。其中，虚线表示键的存在或不存在；R1是取代或未取代的烷基等，R2是取代或未取代的烷氧基等；n为1或2；R3是取代或未取代的芳香环烷基；R4是氢原子等；R5是取代或未取代的芳香环烷基等；Y是单键等；R6是取代或未取代的烷基；R7是—Z—R71等；Z是—NR72—CO—等；R71是取代或未取代的烷基等；R72是氢原子等。
• URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shiro Tomoya

  公开号：US20140179670A1

  公开（公告）日：2014-06-26

  The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R 1 represents a hydrogen atom, a C 1-10 alkyl group, a C 2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R 2 represents a hydrogen atom, a halogen atom, a cyano group, —NR c R d , —N═CHN(CH 3 ) 2 , or an C 1-3 alkyl group; Ar 1 and Ar 2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.

  本发明提供：一种尿嘧啶衍生物，其由通式（I）表示，或其生理上可接受的盐（在该式中，R1代表氢原子，C1-10烷基，C2-6烯基或3-至6-成员饱和或4-至6-成员不饱和的脂肪环基，该环基可以独立地选择来自N，O和S的1到2个杂原子；R2代表氢原子，卤素原子，氰基，—NRcRd，—N═CHN(CH3)2或C1-3烷基；Ar1和Ar2独立地表示5-至6-成员芳香环基，该环基可以独立地选择来自N，O和S的1到3个杂原子；L表示6-成员芳香环基，该环基可以包含1到4个氮原子，吡唑基，三唑基或咪唑基）；以及用作与弹性酶相关的各种炎症性疾病的治疗剂或预防剂，包括该化合物或类似物作为活性成分。
• A process for preparing a substituted oxazole
  申请人：Schering Corporation

  公开号：EP2385050A1

  公开（公告）日：2011-11-09

  A process for producing a compound of formula ID: where R1 is haloalkyl, R2 and R4 are alkyl, R5 is generally hydrogen or alkyl and R6 is an acid labile group, by reacting a compound containing a substituent -C(R3X)NCH2C(O)OR4, where R3 is hydrogen or alkyl and X is O or S, with an alkali metal amide base and a compound R6NHCH(R5)C(O)R7 where R7 is an activated acid moiety.

  一种生产式 ID 化合物的工艺： 其中 R1 为卤代烷基，R2 和 R4 为烷基，R5 一般为氢或烷基，R6 为易受酸作用的基团，其方法是将含有取代基-C(R3X)NCH2C(O)OR4（其中 R3 为氢或烷基，X 为 O 或 S）的化合物与碱金属酰胺基和化合物 R6NHCH(R5)C(O)R7（其中 R7 为活化的酸分子）反应。
• Process for making a substituted oxazole
  申请人：Schering Corporation

  公开号：EP2385051A1

  公开（公告）日：2011-11-09

  A process for making a compound of formula IXab: by reacting an anhydride with a compound containing the group -C(SCH3)NCH2CO2Et to produce an oxazole ester, hydrolysing the ester and reacting with an appropriately protected amino salt to give the desired compound.

  一种制造式 IXab 化合物的工艺： 将酸酐与含有基团-C(SCH3)NCH2CO2Et 的化合物反应生成噁唑酯，水解该酯并与适当保护的氨基盐反应得到所需的化合物。
• Pyrrole amides as alpha V integrin inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10717736B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)化合物或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αv整合素的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含αv整合素失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。